[go: up one dir, main page]

MX2007003271A - Purine derivatives and methods of use thereof. - Google Patents

Purine derivatives and methods of use thereof.

Info

Publication number
MX2007003271A
MX2007003271A MX2007003271A MX2007003271A MX2007003271A MX 2007003271 A MX2007003271 A MX 2007003271A MX 2007003271 A MX2007003271 A MX 2007003271A MX 2007003271 A MX2007003271 A MX 2007003271A MX 2007003271 A MX2007003271 A MX 2007003271A
Authority
MX
Mexico
Prior art keywords
methods
purine derivatives
disorder
purine
purine derivative
Prior art date
Application number
MX2007003271A
Other languages
Spanish (es)
Inventor
Csaba Szabo
Prakash Jagtap
Andrew L Salzman
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of MX2007003271A publication Critical patent/MX2007003271A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention relates to Purine Derivatives; compositions comprising an effectiveamount of a Purine Derivative; and methods for treating or preventing an ischemiccondition, reperfusion injury, a cellular proliferative disorder, a cardiovasculardisease, a neurological disorder, a skin disorder, a radiation-induced injury,a wound, or an inflammatory disease comprising administering an effective amountof a Purine Derivative 'to a subject in need thereof.
MX2007003271A 2004-09-20 2005-09-19 Purine derivatives and methods of use thereof. MX2007003271A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61166904P 2004-09-20 2004-09-20
PCT/US2005/033476 WO2006034190A2 (en) 2004-09-20 2005-09-19 Purine derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2007003271A true MX2007003271A (en) 2007-06-05

Family

ID=36090567

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003271A MX2007003271A (en) 2004-09-20 2005-09-19 Purine derivatives and methods of use thereof.

Country Status (15)

Country Link
US (2) US7863253B2 (en)
EP (1) EP1802316B1 (en)
JP (1) JP5011112B2 (en)
KR (1) KR20070058626A (en)
CN (1) CN101437526A (en)
AT (1) ATE531377T1 (en)
AU (1) AU2005286946B2 (en)
BR (1) BRPI0515506A (en)
CA (1) CA2581132A1 (en)
IL (1) IL182036A0 (en)
MX (1) MX2007003271A (en)
NZ (1) NZ554506A (en)
RU (1) RU2007114887A (en)
WO (1) WO2006034190A2 (en)
ZA (1) ZA200702279B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ532062A (en) * 2001-10-01 2006-09-29 Univ Virginia 2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
SG155182A1 (en) * 2004-08-02 2009-09-30 Univ Virginia 2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity
BRPI0515506A (en) * 2004-09-20 2008-07-29 Inotek Pharmaceuticals Corp purine derivatives and methods of use thereof
NZ568392A (en) * 2005-11-30 2011-07-29 Inotek Pharmaceuticals Corp Purine derivatives and methods of use thereof
WO2007092936A2 (en) * 2006-02-08 2007-08-16 University Of Virginia Patent Foundation Method to treat gastric lesions
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
MX2008012185A (en) * 2006-03-23 2008-10-02 Inotek Pharmaceuticals Corp Purine compounds and methods of use thereof.
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2008124150A1 (en) * 2007-04-09 2008-10-16 University Of Virginia Patent Foundation Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
US10772813B2 (en) 2016-06-03 2020-09-15 Colradel, LLC Compositions and methods of administering a colchicine based topical composition for the prevention of radiation fibrosis
US20220378816A1 (en) * 2019-06-21 2022-12-01 Academy Of Military Medical Sciences 2-benzylidene hydrazinoadenosine compounds having a2a adenosine receptor agonistic activity
US12233053B2 (en) 2021-05-04 2025-02-25 Oradin Pharmaceutical Ltd. Adenosine A3 receptor antagonists for treating aging skin and wounds

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH563405A5 (en) * 1971-09-10 1975-06-30 Duschinsky Robert Dr Schweiz I
JPS58136531A (en) * 1982-02-08 1983-08-13 Ushio Inc Auxiliary head lamp with cover for automobile
US5310731A (en) * 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
PT86660B (en) * 1987-02-04 1992-02-28 Ciba Geigy Ag PROCESS FOR THE PREPARATION OF ADENOSIN-5'-CARBOXAMIDE DERIVATIVES
US5219840A (en) * 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
LU87181A1 (en) * 1987-04-06 1988-11-17 Sandoz Sa NOVEL DERIVATIVES OF FURANNURONIC ACID, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
US5140015A (en) * 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
USRE36494E (en) * 1990-02-20 2000-01-11 Discovery Therapeutics, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5280015A (en) * 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
US5278150A (en) * 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5773423A (en) 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
AU2022497A (en) 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
WO1997033879A1 (en) 1996-03-15 1997-09-18 Merck & Co., Inc. Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
AU750322B2 (en) 1997-05-09 2002-07-18 Trustees Of The University Of Pennsylvania, The Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
US6329349B1 (en) 1997-10-23 2001-12-11 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid A and adenosine receptor agents
CA2317093A1 (en) 1998-01-08 1999-07-15 Joel M. Linden A2a adenosine receptor agonists
GB9813535D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
AU5879299A (en) * 1998-10-16 2000-05-08 Monaghan, Sandra Marina Adenine derivatives
IL127947A0 (en) * 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
NZ516336A (en) * 1999-06-22 2004-01-30 Cv Therapeutics Inc Thiophene A2A receptor agonists
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
GB9924361D0 (en) * 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
US6368573B1 (en) * 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US20010051612A1 (en) * 2000-02-23 2001-12-13 Gloria Cristalli 2-Thioether A2A receptor agonists
US6753322B2 (en) * 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) * 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0015727D0 (en) * 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
CA2434906C (en) 2001-01-16 2008-08-19 Can-Fite Biopharma Ltd. Use of an adenosine a3 receptor agonist for inhibition of viral replication
EP1241176A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
CN103087133B (en) * 2004-05-26 2016-09-14 伊诺泰克制药公司 Purine derivatives as adenosine A1 receptor agonists and their usage
BRPI0515506A (en) * 2004-09-20 2008-07-29 Inotek Pharmaceuticals Corp purine derivatives and methods of use thereof
MX2008012185A (en) * 2006-03-23 2008-10-02 Inotek Pharmaceuticals Corp Purine compounds and methods of use thereof.

Also Published As

Publication number Publication date
US20060128652A1 (en) 2006-06-15
BRPI0515506A (en) 2008-07-29
EP1802316B1 (en) 2011-11-02
US20110059915A1 (en) 2011-03-10
ZA200702279B (en) 2009-03-25
IL182036A0 (en) 2008-11-03
JP5011112B2 (en) 2012-08-29
US8133880B2 (en) 2012-03-13
WO2006034190A2 (en) 2006-03-30
RU2007114887A (en) 2008-10-27
US7863253B2 (en) 2011-01-04
CN101437526A (en) 2009-05-20
KR20070058626A (en) 2007-06-08
ATE531377T1 (en) 2011-11-15
WO2006034190A3 (en) 2008-11-27
JP2008513492A (en) 2008-05-01
AU2005286946B2 (en) 2012-03-15
EP1802316A4 (en) 2010-08-25
CA2581132A1 (en) 2006-03-30
EP1802316A2 (en) 2007-07-04
NZ554506A (en) 2011-01-28
AU2005286946A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
IL182036A0 (en) Purine derivatives and methods of use thereof
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2009106991A3 (en) Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
SI1761266T1 (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
WO2007111954A3 (en) Purine compounds and methods of use thereof
WO2002043652A3 (en) Anti-proliferative drugs
WO2005051429A3 (en) Targeted conjugates with a modified saccharide linker
IL192106A0 (en) Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
MY176679A (en) Use of nutritional compositions for preventing disorders
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
MX2010009625A (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40.
MXPA05000765A (en) 5-aryltetrazole compounds, compositions thereof, and uses therefor.
WO2005065183A3 (en) Mitotic kinesin inhibitors
EA200602197A1 (en) PURINUM DERIVATIVES AS AN AGONISTS OF Adenosine arrestors and methods of their use
WO2008105088A1 (en) Agent for treating spinal cord injury
WO2007109093A3 (en) Pyrazolo[1,5-a]pyrimidine derivatives and methods of use thereof
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
WO2006031348A3 (en) Mitotic kinesin inhibitors
ATE511401T1 (en) COMBINED GENE THERAPY FOR THE TREATMENT OF MACROSCOPIC GLIOMA
BR0317772A (en) Method of treating a behavioral disorder, use of a compound, and therapeutic agent for a behavioral disorder
GB0427637D0 (en) Topical formulations for use in the treatment or prevention of skin cancers
WO2004022039A3 (en) Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system
BR0314647A (en) Use of 4-pyridylmethylphthalazine derivatives for the preparation of a medicament for the treatment of melodysplastic syndromes

Legal Events

Date Code Title Description
FG Grant or registration
HH Correction or change in general